Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
antibiotics
cohort studies
epidemiology
prostate cancer
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
21 Dec 2023
21 Dec 2023
Historique:
received:
17
08
2023
accepted:
26
11
2023
medline:
22
12
2023
pubmed:
22
12
2023
entrez:
22
12
2023
Statut:
aheadofprint
Résumé
Several studies suggest that antibiotic use may affect overall cancer incidence, but the association between antibiotics and prostate cancer is still unclear. This retrospective cohort study aimed to assess the association between antibiotics and the risk of prostate cancer. A population-based retrospective cohort study was conducted using the Korean National Health Insurance Service (NHIS) database. 1 032 397 individuals were followed up from January 1, 2007, to December 31, 2019. Multivariable Cox hazards regression was utilized to calculate adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for the risk of prostate cancer according to accumulative days of antibiotic use and the number of antibiotic classes used from 2002 to 2006. Individuals who used antibiotics for 180 or more days had a higher risk of prostate cancer (aHR, 1.46; 95% CI, 1.11-1.91) than those who did not use antibiotics. Also, individuals who used four or more kinds of antibiotics had a higher risk of prostate cancer (aHR, 1.18; 95% CI, 1.07-1.30) than antibiotic non-users. An overall trend was observed among participants who underwent health examinations. Our findings suggest that long-term use of antibiotics may affect prostate cancer incidence. Further studies are needed to improve understanding of the association between antibiotic use and prostate cancer incidence.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Korea Medical Institute
Organisme : National Research Foundation of Korea (NRF)
Informations de copyright
© 2023 The Japanese Urological Association.
Références
Lin L, Li Z, Yan L, Liu Y, Yang H, Li H. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990-2019. J Hematol Oncol. 2021;14:1-24.
Wang L, Lu B, He M, Wang Y, Wang Z, Du L. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044.
Han HH, Park JW, Na JC, Chung BH, Kim C-S, Ko WJ. Epidemiology of prostate cancer in South Korea. Prostate Int. 2015;3:99-102.
Eeles R, Goh C, Castro E, Bancroft E, Guy M, Olama AAA, et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18-31.
Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, et al. Use of antibiotics and risk of cancer: a systematic review and meta-analysis of observational studies. Cancer. 2019;11:1174.
Kilkkinen A, Rissanen H, Klaukka T, Pukkala E, Heliövaara M, Huovinen P, et al. Antibiotic use predicts an increased risk of cancer. Int J Cancer. 2008;123:2152-2155.
Tamim HM, Hajeer AH, Boivin JF, Collet JP. Association between antibiotic use and risk of prostate cancer. Int J Cancer. 2010;127:952-960.
Kim M, Park SJ, Choi S, Jeong S, Chang J, Park YJ, et al. Association of antibiotic use with risk of lung cancer: a nationwide cohort study. J Infect Public Health. 2023;16:1123-1130.
Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol. 2020;10:572912.
Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191.
Perdana NR, Mochtar CA, Umbas R, Hamid ARA. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones. 2017;48:228-238.
Joung JY. Impact of benign prostatic hyperplasia and/or prostatitis on the risk of prostate cancer in Korean patients. World J Mens Health. 2020:39:358-365.
Daniels NA, Chen Y-H, Bent S. Antibiotic and anti-inflammatory use and the risk of prostate cancer. BMC Res Notes. 2009;2:1-5.
Okada F, Izutsu R, Goto K, Osaki M. Inflammation-related carcinogenesis: lessons from animal models to clinical aspects. Cancer. 2021;13:921.
Okada F. Inflammation-related carcinogenesis: current findings in epidemiological trends, causes and mechanisms. Yonago Acta Med. 2014;57:65-72.
Che B, Zhang W, Xu S, Yin J, He J, Huang T, et al. Prostate microbiota and prostate cancer: a new trend in treatment. Frontiers in Oncology. 2021;11: 805459.
Garbas K, Zapała P, Zapała Ł, Radziszewski P. The role of microbial factors in prostate cancer development-an up-to-date review. J Clin Med. 2021;10:4772.
Elvers KT, Wilson VJ, Hammond A, Duncan L, Huntley AL, Hay AD, et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open. 2020;10:e035677.
Boursi B, Mamtani R, Haynes K, Yang Y-X. Recurrent antibiotic exposure may promote cancer formation-another step in understanding the role of the human microbiota? Eur J Cancer. 2015;51:2655-2664.
Fujita K, Matsushita M, Banno E, De Velasco MA, Hatano K, Nonomura N, et al. Gut microbiome and prostate cancer. Int J Urol. 2022;29:793-798.
Matsushita M, Fujita K, Hatano K, De Velasco MA, Uemura H, Nonomura N. Connecting the dots between the gut-IGF-1-prostate axis: a role of IGF-1 in prostate carcinogenesis. Frontiers in Endocrinology. 2022;13: 852382.
Zhong W, Wu K, Long Z, Zhou X, Zhong C, Wang S, et al. Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 2022;10:1-19.
Li X, Cheng W, Shang H, Wei H, Deng C. The interplay between androgen and gut microbiota: is there a microbiota-gut-testis axis. Reprod Sci. 2021;29:1674-1684.
Westaby D, Fenor de La Maza MD, Paschalis A, Jimenez-Vacas JM, Welti J, de Bono J, et al. A new old target: androgen receptor signaling and advanced prostate cancer. Annu Rev Pharmacol Toxicol. 2022;62:131-153.
Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11-22.
Feldman D, Krishnan A, Moreno J, Swami S, Peehl DM, Srinivas S. Vitamin D inhibition of the prostaglandin pathway as therapy for prostate cancer. Nutr Rev. 2007;65:S113-S115.
Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N. Penetration of antimicrobial agents into the prostate. Chemotherapy. 2003;49:269-279.
Phillips DH, Arlt VM. Genotoxicity: damage to DNA and its consequences. Molecular, Clinical and Environmental Toxicology. Molecular Toxicology. 2009;1:87-110.
David MK, Leslie SW. Prostate specific antigen. StatPearls [Internet]: StatPearls Publishing; 2022.